C
ancer biologists are constantly hunting for tumor-specifi c antigens that can be targeted for monoclonal antibody therapy. Work by Andrea Schietinger, Mary Philip, Hans Schreiber, and colleagues (University of Chicago, IL) reveals that you don't need a mutation in the antigen itself to make it tumor specifi c. Incorrect posttranslational modifi cation will do. The group identifi ed a mutation-free antigen in a spontaneous murine fi brosarcoma, called Ag104A. Mice with this tumor produce a high-affi nity, highly specifi c antibody against what the group now identifi es as a transmembrane protein called OTS8. Although OTS8 is widely expressed, the antibody was only reactive to OTS8 from the Ag104A tumor.
Tumor-derived OTS8 was a different molecular weight than its nonantigenic counterpart yet, to the group's surprise, was not mutated. The different molecular weight was instead due to altered glycosylation. Whereas normal OTS8 contained large sugar moieties, tumor-derived OTS8 predominantly contained a smaller monosaccharide called Tn. This novel combination of Tn and OTS8 created the tumorspecifi c antigen. The defective glycosylation was due to a mutation in a chaperone protein called Cosmc, which controls the activity of a galactosyltransferase enzyme.
A single mutation that leads to defective glycosylation provides the potential for multiple possible antigens, and, encouragingly, Cosmc mutations do not appear to be limited to just one type of tumor. In addition to previously identifi ed Cosmc mutations in a human colon cancer and a T cell leukemia cell line, the team discovered that Cosmc was also mutated in a murine neuroblastoma that also overexpressed Tn.
Certain human cancers are known to overexpress Tn. If patients with these cancers have Cosmc mutations, it would strongly suggest that the tumor cells express many incorrectly glycosylated proteins that are potential tumor-specifi c targets for therapy. Reference: Schietinger, A., et al. 2006 . Science. 314:304-308.
GRIFFITHS/MACMILLAN
Tumor-derived OTS8 is not mutated but is a lower molecular weight due to aberrant glycosylation.
SCHREIBER/AAAS
Centrosomes deliver the death blow J ust as a deadly martial arts master channels his inner chi to deliver a fatal strike, cytotoxic T cells (CTLs) channel their toxic secretory granules to strike an infected target cell. New work by Jane Stinchcombe, Gillian Griffi ths, and colleagues (Sir William Dunn School of Pathology, Oxford, UK) reveals that centrosomes do this channeling, going right to the plasma membrane to deliver their secretory granule death blows.
A CTL targets an infected cell by making transitory contact via an immunological synapse. Lytic protein-containing secretory granules are then released at the synapse to kill the target. Traffi cking of the granules to the synapse was known to require transport along microtubules, but just how granules were delivered was unknown.
The general assumption was that CTLs would deliver their secretory granules in the same way that melanocytes deliver pigment for secretion-by transporting it along microtubules, transferring it to the actin cytoskeleton, and then delivering it to the membrane. Griffi ths's group thus looked at actin in CTLs, but found that it is completely cleared away from the synapse.
The authors found that secretory granule movement toward the minus ends of microtubules was suffi cient for killing target cells. Granules thus move toward the centrosome, which associates with microtubule minus ends, not toward plus ends at the plasma membrane.
The team observed that the centrosome itself associates with the membrane in a large number of synapses. They hypothesize that the action of clearing the actin might, via actins' attachment to microtubules, pull the centrosome close enough to the synapse membrane to send out the granules directly. Griffi ths proposes that such direct delivery, without the need for transfer to the actin cytoskeleton, might also explain how the same CTL can engage and disengage synapses rapidly to kill multiple target cells, much like Bruce Lee rapidly defeats multiple opponents when surrounded.
